Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 6, 1999, Pages 737-741

  Rinne, Juha O ^a,b   Ruottinen, Hanna ^a,b   Bergman, Jörgen ^b   Haaparanta, Merja ^b   Sonninen, Pirkko ^c   Solin, Olof ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU PET CENTRE   (Finland)

^c Department of Radiology ^*  (Finland)

Author keywords

Dopamine reuptake, Parkinson's disease; Dopamine transporter; Positron emission tomography

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE TRANSPORTER; FLUORINE 18; LIGAND;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; FOLLOW UP; HUMAN; HYPOKINESIA; MALE; MOTOR SYSTEM; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; RIGIDITY; SCORING SYSTEM; TREMOR;

AGED; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; CAUDATE NUCLEUS; CORPUS STRIATUM; DISABILITY EVALUATION; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LIGANDS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032744340     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.6.737     Document Type: Article

References (46)

1. Rinne JO, Rummukainen J, Paljärvi L, et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.
2. German DC, Manaye K, Smith WK, et al. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-14.
3. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26:766-70.
4. Fearnley J, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
5. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-55.
6. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984;11:174-9.
7. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-60.
8. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal [18F]fluorodopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-55.
9. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;43:423-31.
10. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
11. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
12. Brucke T, Assenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9-24.
13. Rinne JO, Kuikka JT, Bergström KA, et al. Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995;1:47-51.
14. Rinne JO, Kuikka JT, Bergström KA, et al. Striatal dopamine transporter in Parkinson's disease: a study with a new radioligand [123I]β-CIT-FP. Parkinsonism and related disorders 1997;3:77-81.
15. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Synapse 1996;23:321-7.
16. 18F]β-CFT ([18F)WIN 35,428), a radioligand to study dopamine transporter with PET: characterization in human subjects. Synapse 1998;28:244-50.
17. 18F]β-CFT, is reduced in early Parkinson's disease. Synapse 1999;31:119-124.
18. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47: 718-26.
19. Boja JW, Cline EJ, Carroll FI, et al. High potency cocaine analogs: neurochemical, imaging and behavioural studies. Ann NY Acad Sci 1992;654:282-91.
20. Aloyo VJ, Ruffin JS, Pazdalski PS, et al. [3H]WIN 35,428 binding in the caudate nucleus of the rabbit: evidence for a single site on the dopamine transporter. J Pharmacol Exp Ther 1995;273:435-44.
21. Fahn S, Elton RL, and the members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson's disease. Vol II. Florham Park, NJ: Macmillan, 1987:153-63.
22. Bergman J, Solin O. Fluorine-18-labelled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24:677-83.
23. 18F]CFT. Journal of Labelled Compounds and Radiopharmaceuticals 1993;32:137-8.
24. Pellizari CA, Chen GTY, Spelbring DR, et al. Accurate three-dimensional registration of CT, PET and/or MR images of the brain. J Comput Assist Tomogr 198913:20-6.
25. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993:115:1-17.
26. Carpenter MB, Peter P. Nigrostriatal and nigrothalamic fibers in the rhesus monkey. J Comp Neurol 1972;144:93-116.
27. Szabo J. Organization of the ascending striatal afferents in monkeys. J Comp Neurol 1980;189:307-21.
28. Fearnley J, Lees AJ. Pathology of Parkinson's disease. In: DB Calne ed. Neurodegenerative diseases. Philadelphia: Saunders, 1994:545-54.
29. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876.
30. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]CIT/SPECT imaging demonstrates loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7.
31. Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical signs of Parkinson's diseasee best reflect the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
32. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyg!ucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-13.
33. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure and Parkinson's disease, studied with PET. Brain 1990;113: 1539-52.
34. Rinne UK, Sonninen V. Brain catecholamines and their metabolites in parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch Neurol 1973;28:107-10.
35. Bernheimer H, Birkmeyer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-45.
36. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
37. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-76.
38. Laruelle M, Baldwin R, Malison R, et al. SPECT imaging of dopamine and serotonin transporters with [123I]CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
39. Fang J, Yu P. Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-8.
40. Zilla G, Földi P, Held G, et al. The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Polish Journal of Pharmacology and Pharmacy 1986;38:57-67.
41. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after 1-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93.
42. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8.
43. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-40.
44. Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-83.
45. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77:192-201.
46. Leenders KL, Salmon EP, Tyrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-8.